Cholesterol-Lowering Drugs Still Possible Switch Candidates - Juhl
This article was originally published in The Tan Sheet
Executive Summary
FDA's rejection of hypercholesterolemia as a viable OTC drug category is "shortsighted," University of Pittsburgh School of Pharmacy Dean Randy Juhl, PhD, said at a Drug Information Association meeting on "OTCness" in Washington, D.C. Sept. 16-17. Juhl is a former chair of FDA's Nonprescription Drugs Advisory Committee.